161 related articles for article (PubMed ID: 30936059)
1. Functional analysis of clinical response to low-dose IL-2 in patients with refractory chronic graft-versus-host disease.
Whangbo JS; Kim HT; Nikiforow S; Koreth J; Alho AC; Falahee B; Kim S; Dusenbury K; Fields MJ; Reynolds CG; Alyea EP; Armand P; Cutler CS; Ho VT; Antin JH; Soiffer RJ; Ritz J
Blood Adv; 2019 Apr; 3(7):984-994. PubMed ID: 30936059
[TBL] [Abstract][Full Text] [Related]
2. Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children.
Whangbo JS; Kim HT; Mirkovic N; Leonard L; Poryanda S; Silverstein S; Kim S; Reynolds CG; Rai SC; Verrill K; Lee MA; Margossian S; Duncan C; Lehmann L; Huang J; Nikiforow S; Alyea EP; Armand P; Cutler CS; Ho VT; Blazar BR; Antin JH; Soiffer RJ; Ritz J; Koreth J
Blood Adv; 2019 Sep; 3(17):2550-2561. PubMed ID: 31471324
[TBL] [Abstract][Full Text] [Related]
3. Low-dose IL-2 selectively activates subsets of CD4
Hirakawa M; Matos TR; Liu H; Koreth J; Kim HT; Paul NE; Murase K; Whangbo J; Alho AC; Nikiforow S; Cutler C; Ho VT; Armand P; Alyea EP; Antin JH; Blazar BR; Lacerda JF; Soiffer RJ; Ritz J
JCI Insight; 2016 Nov; 1(18):e89278. PubMed ID: 27812545
[TBL] [Abstract][Full Text] [Related]
4. Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD.
Alho AC; Kim HT; Chammas MJ; Reynolds CG; Matos TR; Forcade E; Whangbo J; Nikiforow S; Cutler CS; Koreth J; Ho VT; Armand P; Antin JH; Alyea EP; Lacerda JF; Soiffer RJ; Ritz J
Blood; 2016 Feb; 127(5):646-57. PubMed ID: 26670634
[TBL] [Abstract][Full Text] [Related]
5. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease.
Matsuoka K; Koreth J; Kim HT; Bascug G; McDonough S; Kawano Y; Murase K; Cutler C; Ho VT; Alyea EP; Armand P; Blazar BR; Antin JH; Soiffer RJ; Ritz J
Sci Transl Med; 2013 Apr; 5(179):179ra43. PubMed ID: 23552371
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease.
Koreth J; Kim HT; Jones KT; Lange PB; Reynolds CG; Chammas MJ; Dusenbury K; Whangbo J; Nikiforow S; Alyea EP; Armand P; Cutler CS; Ho VT; Chen YB; Avigan D; Blazar BR; Antin JH; Ritz J; Soiffer RJ
Blood; 2016 Jul; 128(1):130-7. PubMed ID: 27073224
[TBL] [Abstract][Full Text] [Related]
7. Naive and Stem Cell Memory T Cell Subset Recovery Reveals Opposing Reconstitution Patterns in CD4 and CD8 T Cells in Chronic Graft vs. Host Disease.
Soares MV; Azevedo RI; Ferreira IA; Bucar S; Ribeiro AC; Vieira A; Pereira PNG; Ribeiro RM; Ligeiro D; Alho AC; Soares AS; Camacho N; Martins C; Lourenço F; Moreno R; Ritz J; Lacerda JF
Front Immunol; 2019; 10():334. PubMed ID: 30894856
[TBL] [Abstract][Full Text] [Related]
8. A phase 1 study of donor regulatory T-cell infusion plus low-dose interleukin-2 for steroid-refractory chronic graft-vs-host disease.
Whangbo JS; Nikiforow S; Kim HT; Wahl J; Reynolds CG; Rai SC; Kim S; Burden A; Alho AC; Lacerda JF; Alyea EP; Cutler CS; Ho VT; Antin JH; Soiffer RJ; Ritz J; Koreth J
Blood Adv; 2022 Nov; 6(21):5786-5796. PubMed ID: 35475885
[TBL] [Abstract][Full Text] [Related]
9. Organ-specific response after low-dose interleukin-2 therapy for steroid-refractory chronic graft-versus-host disease.
Kim HT; Koreth J; Whangbo J; Nikiforow S; Reynolds CG; Stowe P; Ho VT; Cutler C; Antin JH; Soiffer RJ; Ritz J
Blood Adv; 2022 Aug; 6(15):4392-4402. PubMed ID: 35617682
[TBL] [Abstract][Full Text] [Related]
10. Durability of clinical and immunologic responses to extended low-dose interleukin-2 therapy in patients with refractory chronic graft-versus-host disease.
Donato V; Kim HT; Stowe P; Reynolds CG; Ritz J; Koreth J; Whangbo JS
Front Immunol; 2022; 13():954966. PubMed ID: 36189229
[TBL] [Abstract][Full Text] [Related]
11. Regulatory T Cells in Chronic Graft-Versus-Host Disease After Extracorporeal Photopheresis: Correlation With Skin and Global Organ Responses, and Ability to Taper Steroids.
Denney HA; Whittle RJ; Lai J; Jacques RM; Taylor PC
Transplantation; 2017 Jan; 101(1):204-211. PubMed ID: 27007227
[TBL] [Abstract][Full Text] [Related]
12. Low-dose interleukin-2 as a modulator of Treg homeostasis after HSCT: current understanding and future perspectives.
Matsuoka KI
Int J Hematol; 2018 Feb; 107(2):130-137. PubMed ID: 29234980
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-2 and regulatory T cells in graft-versus-host disease.
Koreth J; Matsuoka K; Kim HT; McDonough SM; Bindra B; Alyea EP; Armand P; Cutler C; Ho VT; Treister NS; Bienfang DC; Prasad S; Tzachanis D; Joyce RM; Avigan DE; Antin JH; Ritz J; Soiffer RJ
N Engl J Med; 2011 Dec; 365(22):2055-66. PubMed ID: 22129252
[TBL] [Abstract][Full Text] [Related]
14. Induced regulatory T cells promote tolerance when stabilized by rapamycin and IL-2 in vivo.
Zhang P; Tey SK; Koyama M; Kuns RD; Olver SD; Lineburg KE; Lor M; Teal BE; Raffelt NC; Raju J; Leveque L; Markey KA; Varelias A; Clouston AD; Lane SW; MacDonald KP; Hill GR
J Immunol; 2013 Nov; 191(10):5291-303. PubMed ID: 24123683
[TBL] [Abstract][Full Text] [Related]
15. A glucocorticoid amplifies IL-2-induced selective expansion of CD4(+)CD25(+)FOXP3(+) regulatory T cells in vivo and suppresses graft-versus-host disease after allogeneic lymphocyte transplantation.
Xie Y; Wu M; Song R; Ma J; Shi Y; Qin W; Jin Y
Acta Biochim Biophys Sin (Shanghai); 2009 Sep; 41(9):781-91. PubMed ID: 19727527
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and immunologic effects of extracorporeal photopheresis plus interleukin-2 in chronic graft-versus-host disease.
Belizaire R; Kim HT; Poryanda SJ; Mirkovic NV; Hipolito E; Savage WJ; Reynolds CG; Fields MJ; Whangbo J; Kubo T; Nikiforow S; Alyea EP; Armand P; Cutler CS; Ho VT; Blazar BR; Antin JH; Ritz J; Soiffer RJ; Koreth J
Blood Adv; 2019 Apr; 3(7):969-979. PubMed ID: 30936057
[TBL] [Abstract][Full Text] [Related]
17. Nonantigen specific CD8+ T suppressor lymphocytes originate from CD8+CD28- T cells and inhibit both T-cell proliferation and CTL function.
Filaci G; Fravega M; Negrini S; Procopio F; Fenoglio D; Rizzi M; Brenci S; Contini P; Olive D; Ghio M; Setti M; Accolla RS; Puppo F; Indiveri F
Hum Immunol; 2004 Feb; 65(2):142-56. PubMed ID: 14969769
[TBL] [Abstract][Full Text] [Related]
18. Maintenance of CD8+ T-cell anergy by CD4+CD25+ regulatory T cells in chronic graft-versus-host disease.
Kim J; Kim HJ; Choi WS; Nam SH; Cho HR; Kwon B
Exp Mol Med; 2006 Oct; 38(5):494-501. PubMed ID: 17079865
[TBL] [Abstract][Full Text] [Related]
19. CD4(+) and CD8(+) regulatory T cells in chronic rhinosinusitis mucosa.
Pant H; Hughes A; Schembri M; Miljkovic D; Krumbiegel D
Am J Rhinol Allergy; 2014; 28(2):e83-9. PubMed ID: 24717938
[TBL] [Abstract][Full Text] [Related]
20. Reduction of Foxp3+ T cell subsets involved in incidence of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Hu Y; Cui Q; Ye Y; Luo Y; Tan Y; Shi J; Huang H
Hematol Oncol; 2017 Mar; 35(1):118-124. PubMed ID: 26439896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
